Up to 40% of patients receiving the standard R-CHOP regimen for diffuse large B-cell lymphoma have refractory disease or relapse. A modified regimen might improve outcomes. New research findings are summarized in a short video. https://nej.md/3rSJ41d | The New England Journal of Medicine

Diffuse large B-cell #lymphoma is typically a fast-growing, aggressive type of non-Hodgkin lymphoma. It affects immune cells called B lymphocytes, a type of white blood cell. | Bristol Myers Squibb

Meet Lena, a survivor who faced stage 1 diffuse large B-cell lymphoma (DLBCL) head-on, and now, she shares her incredible journey from pre-diagnosis to life after cancer. It all began with what seemed like symptoms of a UTI—blood in her urine. Further investigations uncovered a bladder tumor. Unexpectedly, DLBCL was diagnosed post-surgery, despite the absence of typical signs. Lena candidly recounts the challenges of chemotherapy, from severe medication reactions to the emotional impact of hair